Navigation Links
MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
Date:8/19/2007

Three Independent Clinical Trials Initiated with Teplizumab Manufactured at

MacroGenics

ROCKVILLE, Md., Aug. 2 /PRNewswire/ -- MacroGenics, Inc. announced today that its Protege trial is actively enrolling adults and children ages 8 to 35 with recent-onset type 1 diabetes. The global Phase 2/3 clinical trial will evaluate the safety and efficacy of three teplizumab dosing regimens administered at the start of the study and again at six months in individuals who are up to 12 weeks from their diagnosis of type 1 diabetes. "The initiation of the pivotal Protege study is an important milestone for MacroGenics and for the type 1 diabetes research community," stated Dr. Scott Koenig, President and CEO of MacroGenics. "It is also notable that teplizumab is the first CD3 monoclonal therapy targeting type 1 diabetes to reach this stage of clinical development."

Specifically, the Protege study will assess the ability of teplizumab to inhibit the autoimmune attack that destroys insulin-producing pancreatic beta cells in individuals with type 1 diabetes. If teplizumab is effective and has the ability to preserve or protect beta cells of the pancreas, patients may require less injected insulin and their blood glucose levels may be easier to control. Other research has shown that greater control of blood glucose levels can lead to better long-term health outcomes for patients with type 1 diabetes.

Dr. Koenig also commented, "We are pleased to announce that Dr. Kevan Herold of Yale University and Dr. Bernhard Hering of the University of Minnesota are leading additional teplizumab studies in type 1 diabetes." The AbATE and Delay studies, led by Dr. Herold, are evaluating the safety and efficacy of teplizumab in patients who have had the disease for up to one year. Dr. Hering is evaluating the use of teplizumab as an induction therapy in pancreatic islet cell transplantation.

Additional information regarding the studies i
'/>"/>

SOURCE MacroGenics, Inc.

Copyright©2007 PR Newswire.

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
3. New Study Reveals Limitations of a Complex and Challenging Global Tuberculosis Drug Marketplace
4. Global Rabies Treatment May be Possible with NanoViricides Drugs
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2008)...unt of research reflects depth and breadth of, co...p new treatments for divers... impact of Zometa(R), the leading IV, bisphosphona...reast cancer, - Four oral sessions to feature RAD...f mTOR, including first results of RECORD-1 study ...
(Date:5/15/2008)...TOULOUSE, France, May 15 /- Cerenis,T...eutical company,developing HDL-related compounds f...iseases, today announced that it has completed a P...any,s lead product candidates.,CER-002 is a peroxi...specific agonist in development for the treatment ...
(Date:5/15/2008)...Remains for an Antiplatelet Therapy that, Combined...ination of Plavix/Iscover and Aspirin, Accordi...AM, Mass., May 15 /- Decision Resourc...ry firms for pharmaceutical and,healthcare issues,...ers,improvement in patient compared to Sanofi-Aven...
(Date:5/15/2008)...15 /- Omega 3 fatty acids bound to,ph... credible natural,alternative and may have benefic... in vivo French study reveals. While several studi...hyperactivity, French researchers have,hypothesize...ffects on,impulse control., These research findin...
Breaking Medicine Technology:Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 3Ceramic heal thyself 2960 1Ceramic heal thyself 2960 2Accenx Technologies Announces New Leadership in Sales and Marketing Division 17219 1Accenx Technologies Announces New Leadership in Sales and Marketing Division 17219 221st Congress of the College of Neuropsychopharmacology 17215 121st Congress of the College of Neuropsychopharmacology 17215 2Computer Program Helps COPD Patients Monitor Breathing 17212 1Computer Program Helps COPD Patients Monitor Breathing 17212 2
... 2007 /PRNewswire-FirstCall/ -- Boston,Scientific ...rticle,in the Journal of of Cardiology (JACC) revi...tes the Company,s second-generation,TAXUS(R) Liber...icle in the April 24 edition of JACC concluded tha...e of the TAXUS Liberte Stent,system compared to th...
...--Jun 4, 2007 - Pfizer announced today that,axitin... inhibitor,of VEGFR 1, 2,3 (vascular endothelial g...itabine showed a trend towards prolonged,overall s...cancer,compared with gemcitabine alone, according...ial., These data were presented at the 43rd Americ...
Other Medicine Technology:Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology 2Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology 3Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology 4New Data Show Pfizer's Axitinib Prolonged Overall Survival in,Advanced Pancreatic Cancer When Combined with Standard of Care,Chemotherapy 2New Data Show Pfizer's Axitinib Prolonged Overall Survival in,Advanced Pancreatic Cancer When Combined with Standard of Care,Chemotherapy 3New Data Show Pfizer's Axitinib Prolonged Overall Survival in,Advanced Pancreatic Cancer When Combined with Standard of Care,Chemotherapy 4
(Date:5/17/2008)...f a partial blockage last fall , , SATUR... Edward M. Kennedy was taken from a local hospital...assachusetts General Hospital in Boston early Satu...d possibly a second one, according to news reports... hospital, according to an early afternoon news re...
(Date:5/17/2008)...ather to tell motorists ,Click It or Ticket ...hoolers display art and videos promoting seat belt...t: Local kickoff of the 2008 "Click It or Ticket... Monday, May 19, 2008 Noon (free buffet l...here: The Cleveland House of Blues 308 E...
(Date:5/16/2008)...ire/ -- In the aftermath of central China,s,earthq... their lives, and,over 150,000 were injured. An es... 4 million who have lost their homes. With great s...upreme Master Ching Hai donated an,additional US$3...s from,Supreme Master Ching Hai International Asso...
(Date:5/16/2008)NEW YORK, May 16 /PRNewswire/ -- There,s more to a healthy mouth than,flashing a set of pearly whites. Here,s the scoop on America,s oral care,habits - and what it means for our overall health.,
Breaking Medicine News(10 mins):Health News:Sen. Edward Kennedy Hospitalized After Seizure 2Health News:Northeast Ohio Kicks Off the 2008 Click It or Ticket Campaign 2Health News:Northeast Ohio Kicks Off the 2008 Click It or Ticket Campaign 3Health News:Supreme Master Ching Hai International Association Delivering US$160,000 in Aid to Earthquake Survivors in China 2
... at Stanford University School of Medicine and the...tes that more than 20 percent of low weight new- ...ould have been prevented. The babies would have s...fferent hospitals. Risky deliveries should be refe...
...The Journal of Strength and Conditioning Research ...experience a lowered response to resistance train...udy compared the response to a supervised upper ar...rogram in healthy, young adults who are overweight...
...cterium, Clostridium botulinum, produces the world...wipe off humanity from the face of the earth! Boto...is used medically. Now, the genome of the organis...esearch reveals that the bacterium does not posses...
...ults for the use of bronchial thermoplasty procedu...(RISA) Trial , at the annual scientific assembly ...mson,MD, Professor of Respiratory Medicine, Univer... from Asthmatx, Inc., a medical device company tha...
Other Medicine News:Health News:Low Weight Newborns at Greater Risk in Community Hospitals 2Health News:Low Weight Newborns at Greater Risk in Community Hospitals 3Health News:Genome of Botulism Bacterium Revealed 2Health News:Genome of Botulism Bacterium Revealed 3Health News:Bronchial Thermoplasty: Boon to Severe Asthma Patients? 2
...sthesia and Respiratory Products, ,Westmed design...al devices for Anesthesia and Respiratory professi...oducts that enhance the clinician's ability to del...tion to the bottom line. , ,Our web site is desig...
...sthesia and Respiratory Products, ,Westmed design...al devices for Anesthesia and Respiratory professi...oducts that enhance the clinician's ability to del...tion to the bottom line. , ,Our web site is desig...
... medication nebulizer achieves optimum lung penetr...MMAD particle size range is 1.04-1.10 µ at 6...sor or air outlet., ,As the world leader in airwa...oviders the assurance of proven technology by offe...
... medication nebulizer achieves optimum lung penetr...MMAD particle size range is 1.04-1.10 µ at 6...sor or air outlet., ,As the world leader in airwa...oviders the assurance of proven technology by offe...
Medicine Products: